Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept vs adalimumab on methotrexate in early seropositive rheumatoid arthritis with shared epitope alleles
jRCT2071210068Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Randomised, single-blind trial of abatacept, adalimumab and methotrexate in rheumatoid arthritis (RA) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: ACR50 response at Week 24. Started Nov 2021; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2071210068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210068.